Sign up
Pharma Capital

Valirx's talks in lung cancer highlight progress on all fronts

Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.
Valirx is focused on cancer treatments

ValiRx Plc’s (LON:VAL) has made notable progress across its portfolio over the past twelve months.

In June, the biotech said “advanced conversations” were underway with possible partners as it looked to press ahead with the development of its VAL401 lung cancer candidate.

Earlier this year, the AIM-quoted firm released the results from a phase II trial which confirmed that the drug had a “statistically significant” improvement in overall survival for patients with non-small cell lung cancer compared to those receiving no treatment.

The data also showed that VAL401 had a “measurable improvement” on a patient’s quality of life.

Since then, ValiRx has been further analysing the results and discussing them with various industry opinion leaders and oncology specialists.

Suzy Dilly, the chief executive of ValiSeek – the joint venture company which has developed VAL401 –  also attended the BIO International Convention in Boston in June where she met with potential partners to discuss possible partnerships.

“The external validation from both the Advisory Board and wider industry, has provided increased confidence that VAL401, the product, has a valued and needed place in the market,” said Dilly.

Prostate dosing

Valirx's prostate cancer treatment, VAL201, has also been cleared for a much higher dose to be tested after a phase I/II clinical trial in men with prostate cancer went well.

The change to the Phase I/II dose escalation study will help ValiRx assess the stage in the cancer’s progression at which VAL201 is most effective.

This, in turn, will allow the drug developer to plan “larger, outcome-oriented clinical trials”.

Again, Valirx will seek a partner to help fund a much larger study of the cancer treatment.

Elsewhere, an optimised version of the VAL101 compound was found to be effective in inducing programmed cell death in cancer cell models, a process called apoptosis.

The company said the results showed a “superior apoptotic effect in comparison to currently available reagents”.

Finally, VAL301 is in late pre-clinical phase initially for the treatment of the gynaecological condition, endometriosis

Cash raised

As a result of the programmes it is working on, Valirx is still burning through a decent amount of cash and raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.

Shares were issued in the placing at 2p and have since risen to 2.5p.


Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.